Johnson & Johnson (NYSE:JNJ) Shares Sold by Strengthening Families & Communities LLC

Strengthening Families & Communities LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 90.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,970 shares of the company’s stock after selling 18,391 shares during the period. Strengthening Families & Communities LLC’s holdings in Johnson & Johnson were worth $285,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of JNJ. Peterson Wealth Services boosted its stake in Johnson & Johnson by 5.4% in the 4th quarter. Peterson Wealth Services now owns 13,111 shares of the company’s stock worth $1,896,000 after purchasing an additional 669 shares during the period. Stonebridge Financial Group LLC purchased a new position in Johnson & Johnson during the 4th quarter valued at about $4,817,000. BostonPremier Wealth LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter worth approximately $659,000. Violich Capital Management Inc. grew its position in Johnson & Johnson by 2.6% during the fourth quarter. Violich Capital Management Inc. now owns 100,217 shares of the company’s stock valued at $14,493,000 after purchasing an additional 2,539 shares in the last quarter. Finally, Mill Creek Capital Advisors LLC increased its stake in Johnson & Johnson by 0.5% in the 4th quarter. Mill Creek Capital Advisors LLC now owns 248,661 shares of the company’s stock valued at $35,961,000 after buying an additional 1,144 shares during the period. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now directly owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Trading Down 0.7 %

Johnson & Johnson stock opened at $156.20 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The stock has a market cap of $376.08 billion, a price-to-earnings ratio of 23.49, a price-to-earnings-growth ratio of 2.46 and a beta of 0.52. The business has a 50 day moving average price of $147.73 and a two-hundred day moving average price of $156.01. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.99 by $0.05. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.29 EPS. As a group, equities analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.18%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is 74.59%.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research reports. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 25th. Argus raised shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Wolfe Research started coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 price target on the stock. Leerink Partners reduced their price objective on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research note on Thursday, January 23rd. Finally, Citigroup reduced their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research report on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.67.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.